PWE-025 Assessing the Percent of Days Linaclotide Improved Abdominal Symptoms and Stool Frequency in Patients with Irritable Bowel Syndrome with Constipation (IBS-C): Pooled Analysis of 2 Phase 3 Trials: Abstract PWE-025 Table

IBS-C irritable bowel syndrome with constipation

Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.

Linaclotide is a secretagogue that provides a combined effect on visceral pain. The European Medicines Agency has authorized its indication for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation in adults. The purpose of this review is to discuss the clinical framework for linaclotide use in our setting, the drug´s characteristics and pre-clinical develop...

Linaclotide for irritable bowel syndrome with constipation: a review

2015 Irritable bowel syndrome (IBS) is a common disorder that poses a management challenge. IBS with constipation as the dominant bowel habit is a common phenotype and features abdominal pain, infrequent bowel movements or difficult defecation, bloating and distention, as major symptoms. While laxatives increase stool frequency, they have little impact on other symptoms; prior, more specificall...

The Effect of Written Expression on Severity of Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

Background & Aims: Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal disorders that significantly affects patients' quality of life. This study aimed to determine the effect of written expression on the severity of gastrointestinal symptoms in patients with IBS.  Materials & Methods: This clinical trial study was conducted in 2019 on 71 patients with IBS who were referr...

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C

BACKGROUND US Food and Drug Administration (FDA) set a rigorous standard for defining patient responders in irritable bowel syndrome-C (IBS-C; i.e., FDA's Responder Endpoint) for regulatory approval. However, this endpoint's utility for health-care practitioners to assess clinical response has not been determined. We analyzed pooled IBS-C linaclotide trial data to evaluate clinically significan...